Marketing therapeutic areas

BioPrint consists of a large database and a set of tools with which both the data and the models generated from the data can be accessed. The database contains structural information, in vivo and in vitro data on most of the marketed pharmaceuticals and a variety of other reference compounds. The in vitro data generated consist of panels of pharmacology and early ADME assays. The in vivo data consist of ADR data extracted from drug labels, mechanisms of action, associated therapeutic areas, pharmacokinetic (PK) data and route of administration data. 

Among the compound details collected are the following drug indication, therapeutic area, market status including country and approval status, trade names, routes of administration and chemical class. For most of these data types, there is information on more than 1200 drugs. 

EMEA, CHMP. Guideline on therapeutic Areas Within the Mandatory Scope of the Centralised Procedure for Evaluation for Marketing Authorisation Application, October 2005. 

The pharmaceutical market is highly complex there are a large number of therapeutic areas, differences in the ways countries use medicines and many companies competing in the market place. Unlike most other global industries the pharmaceutical industry is highly fragmented and even... 

There are currently five clinical evaluation units within DSEB, each headed by a senior medical officer and supported by pharmacists. Applications are distributed among the five evaluation units based on the therapeutic area of the drug under evaluation. The DSEB contracts a number of external clinical evaluators who are specialist medical practitioners in the medical condition that the proposed new drug is intended to treat. External evaluators may also be contracted to evaluate the Module 4 data. The head of the clinical evaluation unit coordinates the evaluation and makes the final decision on marketing approval as a delegate under the Therapeutic Goods Act. 

In order to generate the background information for the 5-year plan a complete examination of the existing portfolio is required a review of all activities which affect the conduct of the business. A number of different perspectives are required in order to describe the company s evolution to the current point. These will include activities at subsidiary level and by therapeutic area. They examine activities from the perspective of research, development, manufacturing and marketing. The company s performance will be studied intrinsically and also against competitive benchmarks at product level, therapeutic area level and corporate level. 

None of these is independent of the other products may be brought into development along the timeline of vintages these may be inserted into one or more therapeutic areas and matched for their profit or market size. Major brands can be reinforced by life-cycle management initiatives including new formulations to extend the main franchise, different forms to suit a wider catchment of patients and the extension to new indications possibly by the use of different or novel formulations at the same time. 

Provide an analysis of the advanced dmg delivery market in terms of therapeutic areas... 

Independent National Procedure If a company wishes to market a product in one country only and there are no legal obligations to use a route other than the national one (which would apply if the type of drug or therapeutic area were within the scope of the centralized procedure), then an application can be made to one health authority, leading to a marketing authorization in that country alone. 

The list of indications will be the same for all clinical candidates considered to interfere with TNF and its actions. The primary indication (i.e., the therapeutic area with the biggest market and greatest sales potential as well as suffering where the TNF response is excessive) is rheumatoid arthritis (RA). The secondary indication is inflammation, the tertiary psoriasis and sepsis, and it is also involved in muscle wasting and implicated in cancer. 

What should govern corporate strategies in a fragmented market The market is by definition fragmented because no company has more than 8 to 10% of the total market. For a therapeutic area such as cardiovascular disease or oncology or psychiatry, however, there are companies that have up to 25% of the market. 

Chronologically, natural product therapeutic antibacterials entered the market place in the 1940 s, shortly followed by the feed additive antibacterials. The first anticoccidial agents appeared at the beginning of the 1970 s. As we have seen in all these therapeutic areas, natural product products quickly grew to a high proportion of the market sector. 

---